Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory

Affiliations

¹ Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁵ Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁶ Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC, USA.
⁷ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁸ Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁹ School of Biomedical Informatics, The University of Texas Health Science Center at Houston, TX, USA.
¹⁰ Division of General Internal Medicine, Medical School, The University of Texas Health Science Center at Houston, TX, USA.
¹¹ Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹² Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Published Erratum

Natalia Paez Arango et al. Oncotarget. 2019.

. 2019 Aug 27;10(50):5254.

doi: 10.18632/oncotarget.27176.

¹ Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁵ Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁶ Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC, USA.
⁷ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁸ Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁹ School of Biomedical Informatics, The University of Texas Health Science Center at Houston, TX, USA.
¹⁰ Division of General Internal Medicine, Medical School, The University of Texas Health Science Center at Houston, TX, USA.
¹¹ Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹² Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Abstract

[This corrects the article DOI: 10.18632/oncotarget.16018.].

A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory.
Arango NP, Brusco L, Mills Shaw KR, Chen K, Eterovic AK, Holla V, Johnson A, Litzenburger B, Khotskaya YB, Sanchez N, Bailey A, Zheng X, Horombe C, Kopetz S, Farhangfar CJ, Routbort M, Broaddus R, Bernstam EV, Mendelsohn J, Mills GB, Meric-Bernstam F. Arango NP, et al. Oncotarget. 2017 Jun 27;8(26):41806-41814. doi: 10.18632/oncotarget.16018. Oncotarget. 2017. PMID: 28415679 Free PMC article.